2024
Acute pancreatitis: pathogenesis and emerging therapies
Zaman S, Gorelick F. Acute pancreatitis: pathogenesis and emerging therapies. Journal Of Pancreatology 2024, 7: 10-20. PMID: 38524855, PMCID: PMC10959536, DOI: 10.1097/jp9.0000000000000168.Peer-Reviewed Original ResearchAcute pancreatitisSevere inflammatory disordersLimited treatment optionsLong-term outcomesPotential treatment benefitsPromising new therapyDisease mechanismsPotential therapeutic targetEmerging TherapiesAcute injuryInflammatory disordersPharmacologic interventionsTreatment optionsTreatment benefitPotential therapyNew therapiesSpecific treatmentTherapeutic targetNew treatmentsTherapyPancreatitisTreatmentComplicationsPathogenesisInjury
2019
CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation
Esteghamat F, Broughton JS, Smith E, Cardone R, Tyagi T, Guerra M, Szabó A, Ugwu N, Mani MV, Azari B, Kayingo G, Chung S, Fathzadeh M, Weiss E, Bender J, Mane S, Lifton RP, Adeniran A, Nathanson MH, Gorelick FS, Hwa J, Sahin-Tóth M, Belfort-DeAguiar R, Kibbey RG, Mani A. CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation. Nature Genetics 2019, 51: 1233-1243. PMID: 31358993, PMCID: PMC6675645, DOI: 10.1038/s41588-019-0470-3.Peer-Reviewed Original ResearchConceptsEarly-onset atherosclerosisMetabolic syndromeMetabolic syndrome traitsWhole-exome sequence analysisAttractive therapeutic targetPlatelet hyperactivationInsulin levelsPlasma insulinPlasma levelsInsulin sensitivityInsulin secretionTherapeutic targetPlatelet activationDisease mechanismsSyndrome traitsAtherosclerosisFunction mutationsSyndromeNovel lossInsulinMutationsSecretion
2017
Do Animal Models of Acute Pancreatitis Reproduce Human Disease?
Gorelick FS, Lerch MM. Do Animal Models of Acute Pancreatitis Reproduce Human Disease? Cellular And Molecular Gastroenterology And Hepatology 2017, 4: 251-262. PMID: 28752114, PMCID: PMC5518169, DOI: 10.1016/j.jcmgh.2017.05.007.Peer-Reviewed Original ResearchAcute pancreatitisBiological disease mechanismsNonmalignant gastrointestinal diseasesPathophysiological disease mechanismsDisease mechanismsPotential therapeutic targetPaucity of dataHospital admissionCommon causeExperimental pancreatitis modelGastrointestinal diseasesPancreatitis modelTherapeutic targetAnimal modelsNatural historySpecific causesDiseaseDisease modelsPancreatitisDisease developmentUnderlying cellMolecular mechanismsHuman diseasesCauseLimited information
2016
Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer
Guo X, Hollander L, MacPherson D, Wang L, Velazquez H, Chang J, Safirstein R, Cha C, Gorelick F, Desir GV. Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. Scientific Reports 2016, 6: 22996. PMID: 26972355, PMCID: PMC4789641, DOI: 10.1038/srep22996.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsAntibodiesApoptosisCarcinoma, Pancreatic DuctalCell Cycle CheckpointsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateMaleMice, NudeMiddle AgedMonoamine OxidasePancreatic NeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReverse Transcriptase Polymerase Chain ReactionRNA InterferenceSignal TransductionXenograft Model Antitumor AssaysConceptsRenalase expressionPancreatic cancerPancreatic ductal adenocarcinoma growthCohort of patientsPancreatic cancer tissuesPancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma cellsXenograft mouse modelAttractive therapeutic targetDuctal adenocarcinoma cellsTumor cell apoptosisOverall survivalPathogenic roleCell cycle arrestDuctal adenocarcinomaPrognostic makerTumor massMouse modelTherapeutic targetCellular injuryCancer tissuesRenalaseCancerAdenocarcinoma cellsGrowth factor
2010
Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease
He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, Bettayeb K, Flajolet M, Gorelick F, Wennogle LP, Greengard P. Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease. Nature 2010, 467: 95-98. PMID: 20811458, PMCID: PMC2936959, DOI: 10.1038/nature09325.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseGamma-secretase activating proteinDisease drugsBlood-brain barrierSevere side effectsΓ-secretase activating proteinPossible new targetsAlzheimer's disease drugsNotch cleavageSide effectsTherapeutic targetActivating proteinHomeostatic functionsAnti-Alzheimer drugsDiseaseNew targetsΓ-secretaseAnticancer drug imatinibProcessing of NotchDrugsDrug imatinibImatinibBrain
2006
Phospholipase D1 corrects impaired βAPP trafficking and neurite outgrowth in familial Alzheimer’s disease-linked presenilin-1 mutant neurons
Cai D, Zhong M, Wang R, Netzer WJ, Shields D, Zheng H, Sisodia SS, Foster DA, Gorelick FS, Xu H, Greengard P. Phospholipase D1 corrects impaired βAPP trafficking and neurite outgrowth in familial Alzheimer’s disease-linked presenilin-1 mutant neurons. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 1936-1940. PMID: 16449385, PMCID: PMC1413666, DOI: 10.1073/pnas.0510710103.Peer-Reviewed Original ResearchConceptsTrans-Golgi networkOverexpression of PLD1Mutant neuronsPhospholipase D1Beta-amyloid precursor proteinIntracellular traffickingPS1-deficient cellsPLD enzymatic activityTherapeutic targetNeuronal functionPS1 mutationsOverexpression of WTBetaAPPPrecursor proteinMutant cellsSubcellular localizationNeurite outgrowthPLD1 activitySurface deliveryNeuronsOutgrowth capacityCellsTraffickingEnzymatic activityOverexpression